New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
08:25 EDTROIL, ROIL, PFIE, PFIE, ARSD, ARSD, UUUU, UUUU, SRNE, SRNE, VTEQ, VTEQ, SNWV, SNWV, OPXA, OPXA, CGIX, CGIX, GALT, GALT, OGEN, OGENRedChip Companies to hold a virtual conference
RedChip Virtual Conference to be held on April 23-24 with webcasted company presentations to begin on April 23 at 8:30 am. Webcast Link
News For OGEN;GALT;CGIX;OPXA;SNWV;VTEQ;SRNE;UUUU;ARSD;PFIE;ROIL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
09:06 EDTSRNESorrento Therapeutics announces positive results from Tribeca trial
Subscribe for More Information
May 1, 2015
13:15 EDTSRNESorrento acquires South American rights to Cynviloq
Sorrento Therapeutics announced that its fully owned subsidiary, IGDRASOL, has acquired exclusive distribution rights from Samyang Biopharmaceuticals, a South Korean corporation, to Cynviloq in South America.
10:17 EDTPFIEProfire Energy management to meet with Maxim
Subscribe for More Information
April 30, 2015
16:56 EDTSRNESorrento Therapeutics appoints Mark Durand as CFO
Subscribe for More Information
April 27, 2015
10:00 EDTPFIEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:33 EDTPFIEProfire Energy initiated with an Outperform at Barrington
Subscribe for More Information
April 23, 2015
07:07 EDTPFIE, GALT, CGIXRedChip to hold a virtual conference
Subscribe for More Information
April 22, 2015
07:16 EDTPFIE, GALT, CGIXRedChip to hold a virtual conference
Subscribe for More Information
April 20, 2015
08:10 EDTOPXAOpexa Therapeutics to present biomarker data from NMO patients at AAN meeting
Opexa Therapeutics announced that it has been invited to present data on the immune profile of patients with NMO at the 67th American Academy of Neurology Annual Meeting in Washington D.C. Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use